Caris
Caris Life Sciences Expands Access to Urologic Cancer Tests Through Deal With Lumea
The firms agreed to make Caris' whole-exome and whole-transcriptome sequencing tests available through Lumea's BxLink digital pathology software.
Caris Life Sciences CDx Assay Nabs FDA Approval
The whole-exome sequencing and whole-transcriptome sequencing-based test is approved for molecular profiling of solid tumors.
Caris Life Sciences, ECOG-ACRIN to Analyze Breast Tumor Samples From Landmark TAILORx Study
Through a new partnership, Caris will use its comprehensive genomic profiling tests to sequence more than 10,000 early-stage breast tumors collected in TAILORx.
Researchers are planning a clinical trial after four metastatic FGFR2 fusion-positive pancreatic cancer patients responded to FGFR-directed therapy.
Caris Life Sciences, EDX Medical Ink Molecular Profiling Distribution Agreement
EDX Medical has the exclusive rights to distribute Caris' portfolio of molecular profiling services throughout the UK and four Nordic countries.